Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...